Midostaurin

BreastfeedingGeriatricPediatric
  • TRADE NAME: Rydapt (Novartis)
  • INDICATIONS: Aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia; acute myeloid leukemia (FLT3 mutation-positive) in combination with cytarabine and daunorubicin induction and cytarabine consolidation
  • CLASS: Multikinase inhibitor
  • HALF-LIFE: 21 hours

FDA APPROVAL DATE: 04/28/2017

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Boceprevir, Carbamazepine, Clarithromycin, Cobicistat, Conivaptan, Danoprevir, Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir, Diltiazem, Elvitegravir, Enzalutamide, Grapefruit Juice, Idelalisib, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Mitotane, Nefazodone, Nelfinavir, Ombitasvir/Paritaprevir/Ritonavir, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Stong CYP3A inducers and inhibitors, Tipranavir, Troleandomycin, Voriconazole

PREGNANCY CATEGORY: N/A
May cause fetal toxicity based on findings in animal studies

Our database has 81 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
GENITOURINARY
RENAL
HEMATOLOGIC
OTHER


Page last updated 08/08/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric